日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.

靶向钍-227偶联物在获得性耐药的临床前模型中显示出疗效,并具有与化疗药物和抗血管生成疗法联合应用的潜力

Zitzmann-Kolbe Sabine, Kristian Alexander, Zopf Dieter, Kamfenkel Claudia, Politz Oliver, Ellingsen Christine, Hilbig Jochen, Juul Mark U, Fonslet Jesper, Nielsen Carsten H, Schatz Christoph A, Bjerke Roger M, Cuthbertson Alan S, Mumberg Dominik, Hagemann Urs B

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy

靶向钍-227偶联物作为单药及与抗PD-L1疗法联合应用时的免疫刺激作用

Lejeune, Pascale; Cruciani, Véronique; Berg-Larsen, Axel; Schlicker, Andreas; Mobergslien, Anne; Bartnitzky, Lisa; Berndt, Sandra; Zitzmann-Kolbe, Sabine; Kamfenkel, Claudia; Stargard, Stefan; Hammer, Stefanie; Jørgensen, Jennifer S; Jackerott, Malene; Nielsen, Carsten H; Schatz, Christoph A; Hennekes, Hartwig; Karlsson, Jenny; Cuthbertson, Alan S; Mumberg, Dominik; Hagemann, Urs B

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab

体外和体内比较 3,2-HOPO 与去铁胺螯合锆-89 与抗皮素抗体 Anetumab 的效果

Roy, Jyoti; Jagoda, Elaine M; Basuli, Falguni; Vasalatiy, Olga; Phelps, Tim E; Wong, Karen; Ton, Anita T; Hagemann, Urs B; Cuthbertson, Alan S; Cole, Patricia E; Hassan, Raffit; Choyke, Peter L; Lin, Frank I

Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy

精准肿瘤学进展:靶向钍-227偶联物作为靶向α疗法的新模式

Hagemann, Urs B; Wickstroem, Katrine; Hammer, Stefanie; Bjerke, Roger M; Zitzmann-Kolbe, Sabine; Ryan, Olav B; Karlsson, Jenny; Scholz, Arne; Hennekes, Hartwig; Mumberg, Dominik; Cuthbertson, Alan S